Related Experiment Video
Updated: Jun 29, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.0K
Automatic classification of AD pathology in FTD phenotypes using natural speech.
Sunghye Cho1, Christopher A Olm2, Sharon Ash2
1Linguistic Data Consortium, Department of Linguistics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Summary
Speech analysis can identify Alzheimer's disease neuropathologic change (ADNC) in frontotemporal dementia (FTD) patients. This technology aids in early diagnosis and supports the development of digital screening tools for FTD.
Area of Science:
- Neuroscience
- Artificial Intelligence
- Speech Pathology
Background:
- Screening for Alzheimer's disease neuropathologic change (ADNC) in individuals with atypical presentations like frontotemporal dementia (FTD) is clinically challenging.
- Distinguishing ADNC from other pathologies, such as frontotemporal lobar degeneration (FTLD), is crucial for effective patient management.
Purpose of the Study:
- To develop and validate automatic speech-based classifiers for distinguishing FTD patients with ADNC from those with FTLD.
- To identify speech features and their corresponding neuroanatomical correlates associated with different pathologies.
Main Methods:
- Trained automatic classifiers using 99 speech features from 1-minute speech samples of 179 participants (36 ADNC, 60 FTLD, 89 healthy controls).
- Assigned neuropathology based on autopsy or cerebrospinal fluid (CSF) biomarkers.
- Utilized structural network-based magnetic resonance imaging (MRI) to analyze anatomical correlates of speech features.
Main Results:
- The classifier achieved an area under the curve (AUC) of 0.88 ± 0.03 for distinguishing ADNC from FTLD.
- The classifier achieved an AUC of 0.93 ± 0.04 for distinguishing patients from healthy controls.
- Noun frequency and pause rate correlated with gray matter volume loss in the limbic and salience networks, respectively.
Conclusions:
- Brief, naturalistic speech samples are effective for in vivo screening of FTD patients for underlying ADNC.
- This research supports the development of digital assessment tools for FTD, improving diagnostic capabilities.
- The findings highlight the potential of speech analysis combined with AI for non-invasive neuropathology screening.
Related Concept Videos
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184

